Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexmarilimab in Localised Renal Cell and Colon Carcinoma
NCT05104905Phase 2Withdrawn
- Sponsor
- Faron Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bexmarilimab in renal cell carcinoma (RCC), colon carcinoma, sponsored by Faron Pharmaceuticals. Planned start Oct 2021; status: withdrawn.
02
Drugs
bexmarilimab
03
Conditions
renal cell carcinoma (RCC)colon carcinoma
Beyond the preview
Go deeper on NCT05104905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104905.